GlassScriptPhysician profile
Elijah Bernard Stevens
NPI 1326131954
$131,259.03
in general payments reported to CMS, 2019-2025
12 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43K · 2022: $35K · 2023: $16K · 2024: $27K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $5,618 · Consulting Fee: $4,675 · Travel and Lodging: $4,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,775.00 |
| Food and Beverage | $5,617.83 |
| Consulting Fee | $4,675.00 |
| Travel and Lodging | $4,068.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60,763.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51,191.11 | 2021-2025 | Caplyta |
| Alkermes, INC. | $16,878.23 | 2021-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $928.94 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $538.57 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $457.33 | 2021-2025 | Spravato, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $212.24 | 2021 | |
| Axsome Therapeutics, INC. | $165.40 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $38.95 | 2025 | Cobenfy |
| Lundbeck LLC | $36.36 | 2021 | |
| Neurocrine Biosciences, INC. | $31.85 | 2023 | Ingrezza |
| Indivior INC. | $17.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elijah Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.